Entasis Therapeutics Holdings Inc (ETTX)
Stock chart
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2022-07-13 | 2022-07-11 | B Purchase |
Former 10% Owner Large shareholder |
7,598,814
+35.1%
2.20USD 16,717,391 |
7,598,814 +35.1% | 2.20 | USD 16,717,391 | |
| 2022-07-13 | 2022-07-08 | B Purchase |
Former 10% Owner Large shareholder |
11,671,662
+116.7%
2.20USD 25,677,656 |
11,671,662 +116.7% | 2.20 | USD 25,677,656 | |
| 2021-10-20 | 2021-10-19 | S Sale |
General Counsel Officer |
3,759
-7.5%
3.19USD 11,991 |
3,759 -7.5% | 3.19 | USD 11,991 | |
| 2021-10-20 | 2021-10-19 | S Sale |
See Remarks Officer |
3,759
-7.5%
3.19USD 11,991 |
3,759 -7.5% | 3.19 | USD 11,991 | |
| 2021-10-20 | 2021-10-19 | S Sale |
See Remarks Executive Director |
11,974
-7.5%
3.19USD 38,197 |
11,974 -7.5% | 3.19 | USD 38,197 | |
| 2021-10-20 | 2021-10-19 | S Sale |
Chief Development Officer Officer |
4,001
-8.0%
3.19USD 12,763 |
4,001 -8.0% | 3.19 | USD 12,763 | |
| 2021-10-20 | 2021-10-19 | S Sale |
Chief Scientific Officer Officer |
3,759
-5.2%
3.19USD 11,991 |
3,759 -5.2% | 3.19 | USD 11,991 | |
| 2021-10-20 | 2021-10-19 | S Sale |
See Remarks Officer |
3,759
-7.5%
3.19USD 11,991 |
3,759 -7.5% | 3.19 | USD 11,991 | |
| 2021-10-20 | 2021-10-19 | S Sale |
Chief Medical Officer Officer |
3,759
-7.5%
3.19USD 11,991 |
3,759 -7.5% | 3.19 | USD 11,991 | |
| 2020-09-01 | 2020-09-01 | B Purchase | Large shareholder |
4,672,897
+33.4%
2.68USD 12,499,999 |
4,672,897 +33.4% | 2.68 | USD 12,499,999 | |
| 2020-06-12 | 2020-06-11 | B Purchase | Large shareholder |
12,677,490
+958.6%
2.50USD 31,693,725 |
12,677,490 +958.6% | 2.50 | USD 31,693,725 | |
| 2020-01-13 | 2020-01-09 | S Sale |
Frazier Life Sciences VIII, L.P. Large shareholder |
50,000
-3.7%
5.00USD 250,010 |
50,000 -3.7% | 5.00 | USD 250,010 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Topper James N Non-Executive Director Large shareholder |
375,887
+38.6%
15.00USD 5,638,305 |
375,887 +38.6% | 15.00 | USD 5,638,305 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Pivotal bioVenture Partners Fund I, L.P. Large shareholder |
337,724
+40.1%
15.00USD 5,065,860 |
337,724 +40.1% | 15.00 | USD 5,065,860 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Clarus Lifesciences III, L.P. Large shareholder |
453,395
+38.8%
15.00USD 6,800,925 |
453,395 +38.8% | 15.00 | USD 6,800,925 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Preston Heather Non-Executive Director Large shareholder |
337,724
+40.1%
15.00USD 5,065,860 |
337,724 +40.1% | 15.00 | USD 5,065,860 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Sofinnova Venture Partners IX, L.P. Large shareholder |
337,724
+40.1%
15.00USD 5,065,860 |
337,724 +40.1% | 15.00 | USD 5,065,860 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
TPG Group Holdings (SBS) Advisors, Inc. |
262,539
+34.6%
15.00USD 3,938,085 |
262,539 +34.6% | 15.00 | USD 3,938,085 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
ASTRAZENECA PLC Large shareholder |
246,666
+12.9%
15.00USD 3,699,990 |
246,666 +12.9% | 15.00 | USD 3,699,990 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
Frazier Life Sciences VIII, L.P. Large shareholder |
375,887
+38.6%
15.00USD 5,638,305 |
375,887 +38.6% | 15.00 | USD 5,638,305 | |
| 2018-10-02 | 2018-09-28 | B Purchase |
GALAKATOS NICHOLAS Non-Executive Director Large shareholder |
453,395
+38.8%
15.00USD 6,800,925 |
453,395 +38.8% | 15.00 | USD 6,800,925 | |
| 2018-10-01 | 2018-09-28 | B Purchase |
Novo Holdings A/S Large shareholder |
1,089,835
+99.8%
15.00USD 16,347,525 |
1,089,835 +99.8% | 15.00 | USD 16,347,525 |